NASDAQ: AZTAAzenta Inc Stock
$51.50-0.59 (-1.13%)
Updated Apr 25, 2024
AZTA Price
$51.50
Fair Value Price
-$7.90
Market Cap
$2.87B
52 Week Low
$36.01
52 Week High
$69.16
P/E
-156.06x
P/B
1.18x
P/S
5.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$641.02M
Earnings
-$18.75M
Gross Margin
39.1%
Operating Margin
-4.97%
Profit Margin
-2.9%
Debt to Equity
0.16
Operating Cash Flow
$71M
Beta
1.47
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AZTA Overview
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AZTA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AZTA ($51.50) is overvalued by 751.8% relative to our estimate of its Fair Value price of -$7.90 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AZTA ($51.50) is not significantly undervalued (751.8%) relative to our estimate of its Fair Value price of -$7.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AZTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AZTA due diligence checks available for Premium users.
Be the first to know about important AZTA news, forecast changes, insider trades & much more!
AZTA News
Valuation
AZTA fair value
Fair Value of AZTA stock based on Discounted Cash Flow (DCF)
Price
$51.50
Fair Value
-$7.90
Undervalued by
751.80%
AZTA ($51.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZTA ($51.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AZTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-156.06x
Industry
47.92x
Market
40.97x
AZTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
3.49x
AZTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AZTA's financial health
Profit margin
Revenue
$154.3M
Net Income
-$15.7M
Profit Margin
-10.2%
AZTA's Earnings (EBIT) of -$31.85M... subscribe to Premium to read more.
Interest Coverage Financials
AZTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.8B
Liabilities
$380.7M
Debt to equity
0.16
AZTA's short-term assets ($1.38B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZTA's short-term assets ($1.38B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$26.4M
Investing
$98.4M
Financing
-$113.2M
AZTA's operating cash flow ($70.94M)... subscribe to Premium to read more.
Debt Coverage Financials
AZTA vs Medical Stocks
Azenta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.